Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Madhavan Balachandran, a director at Replimune Group, Inc., acquired stock options for 64,000 shares on September 4, 2024.
Summary
- On September 4, 2024, Madhavan Balachandran, a director of Replimune Group, Inc., acquired employee stock options.
- The options grant the right to buy 64,000 shares of common stock at an exercise price of $10.44.
- These options vest over time, with 25% vesting on September 4, 2025, and the remaining shares vesting in 24 equal monthly installments thereafter.
- Following the transaction, Balachandran directly owns 64,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it indicates a director's belief in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of transaction: Director acquired stock options. |
| 09/04/2025 | 25% of the stock options vest. |
| 09/04/2034 | Expiration date of the stock options. |
| 09/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.